Skip to main content
Midas Edge

Milestone Pharmaceuticals Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

MIST$0.66-10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Shareholders’ Equity

Condensed Consolidated Statements of Shareholders’ Equit****y (Unaudited)

(in thousands of U.S. dollars, except share data)

​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Shares · ​ · Pre-funded warrants · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ ​ ​ · Numberof shares · ​ ​ ​ · Amount · ​ ​ ​ · Numberof warrants · ​ ​ ​ · Amount · ​ ​ ​ · Additionalpaid-incapital · ​ ​ ​ · Accumulateddeficit · ​ ​ ​ · Total
Balance as of March 31, 2025​53,464,273​$288,188​12,910,590​$53,076​$40,919​$(388,306)​$(6,123)
Transactions during the three-month period ended June 30, 2025​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(12,966)​​(12,966)
Exercise of stock options​29,988​​75​—​​—​​(39)​​—​​36
Share-based compensation​—​​—​—​​—​​1,308​​—​​1,308
Balance as of June 30, 2025​53,494,261​$288,263​12,910,590​$53,076​$42,188​$(401,272)​$(17,745)
​​​​​​​​​​​​​​​​​​​​
Balance as of March 31, 2026​117,794,417​$373,702​16,412,925​$55,649​$63,367​$(456,669)​$36,049
Transactions during the three-month period ended June 30, 2026​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(28,614)​​(28,614)
Exercise of stock options​24,921​​53​—​​—​​(25)​​—​​28
Exercise of Series A common stock warrants, net of issuance costs​6,678,642​​11,230​—​​—​​(1,813)​​—​​9,417
Share-based compensation​—​​—​—​​—​​1,338​​—​​1,338
Balance as of June 30, 2026​124,497,980​$384,985​16,412,925​$55,649​$62,867​$(485,283)​$18,218
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2024​53,353,984​$288,048​12,910,590​$53,076​$39,568​$(367,545)​$13,147
Transactions during the six-month period ended June 30, 2025​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(33,727)​​(33,727)
Exercise of stock options​29,988​​75​—​​—​​(39)​​—​​36
Share-based compensation​—​​—​—​​—​​2,659​​—​​2,659
Employee stock purchase plan purchases​110,289​​140​—​​—​​—​​—​​140
Balance as of June 30, 2025​53,494,261​$288,263​12,910,590​$53,076​$42,188​$(401,272)​$(17,745)
​​​​​​​​​​​​​​​​​​​​
Balance as of December 31, 2025​106,236,344​$352,619​16,412,925​$55,649​$64,104​$(430,603)​$41,769
Transactions during the six-month period ended June 30, 2026​​​​​​​​​​​​​​​​​​​
Net loss​—​​—​—​​—​​—​​(54,680)​​(54,680)
Exercise of stock options​24,921​​53​—​​—​​(25)​​—​​28
Exercise of Series A common stock warrants, net of issuance costs​12,345,308​​20,759​—​​—​​(3,352)​​—​​17,407
Share-based compensation​—​​—​—​​—​​2,620​​—​​2,620
Issuance of common shares, vesting of restricted stock units​237,677​​480​—​​—​​(480)​​—​​—
Issuance of common shares, net of issuance costs​5,526,590​​10,890​—​​—​​—​​—​​10,890
Employee stock purchase plan purchases​127,140​​184​—​​—​​—​​—​​184
Balance as of June 30, 2026​124,497,980​$384,985​16,412,925​$55,649​$62,867​$(485,283)​$18,218
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.